STA: Eluxadoline for treating irritable bowel syndrome with diarrhoea
As part of the NICE single technology appraisal process, the Aberdeen evidence review group (ERG) critically reviewed the company’s submission related to the clinical and cost-effectiveness of Eluxadoline for treating irritable bowel syndrome with diarrhoea. In terms of clinical effectiveness, the company’s submission focused on evidence from 3 double-blind randomised controlled trials: IBS‑2001 (a phase 2 trial), IBS‑3001 and IBS‑3002 (both phase 3 trials). The economic evidence was based on a Markov decision model informed by the clinical evidence and structured around 16 health states defined by changes in IBS‑QoL (four categories) and pain from baseline (two categories), and treatment status (on and off-treatment).
Outcome and Translation
Based on consideration of evidence submitted by Allergan and a review of these submissions submitted by the evidence review group, NICE recommended Eluxadoline as an option for treating irritable bowel syndrome with diarrhoea in adults meeting certain criteria. Details of the appraisal and the full guidance are available on the NICE website: https://www.nice.org.uk/guidance/ta471
HERU researchers invovled in this project: Graham Scotland
External collaborators: Ramsay, C., Brazzelli, M; Cummins, E; Campbell, M. (Health Services Research Unit (HSRU), University of Aberdeen).
Scotland, G. and Brazzelli, M. (2017) Eluxadoline for treating irritable bowel syndrome with diarrhoea. Evidence Review Group critique of the new economic evidence submitted by the company in response to the Appraisal Consultation Document, (NICE Technology Appraisal Guidance -TA471), Aberdeen Health Technology Assessment Group.